INTROGEN Therapeutics Inc.

INTROGEN Therapeutics Inc. reports positive data from a phase II trial combining Advexin, its investigational adenoviral vector containing the p53 tumor-suppressor gene with radiation therapy. Patients with non-small solitary abode; squalid lung cancer showed a roughly 60 percent regression or

...